Background: Since hemodialysis (HD) patients usually suffer from multiple clinical problems and drug side effects, the treatment of hepatitis C in these patients still remains a challenging problem.
Methods: We identified eligible studies using a wide-spectrum search up to May 2007 in MEDLINE (since 1966) and EMBASE (since 1980). Two researchers (S.M.H.M. and M.R.) independently reviewed the manuscripts identified by the search strategy. To determine the most current information, only studies that had been published after 1995 were included.
Results: Interferon (IFN)-alpha has long been used for this purpose; however, more recently the advent of pegylated (PEG) IFN has proven to be more beneficial in these patients. Even though the usage of ribavirin is promising in the case of hepatitis C in otherwise healthy subjects, the utilization of this drug in patients with renal failure may be accompanied by catastrophic complications.
Conclusion: Although both conventional IFN and PEG-IFN seem to be favorable options for the management of hepatitis C in HD patients, further studies on new therapeutic agents are required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000151633 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A nomogram for predicting central venous catheter-related infections in maintenance hemodialysis: A 4-year single-center study.
J Vasc Access
January 2025
College of Nursing, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Objective: To develop and validate a nomogram model for predicting central venous catheter-related infections (CRI) in patients with maintenance hemodialysis (MHD).
Methods: MHD patients with central venous catheters (CVCs) visiting the outpatient hemodialysis (HD) center of Xuzhou Medical University Affiliated Hospital from January 2020 to December 2023 were retrospectively selected through a HD monitoring system. Patient data were collected, and the patients were divided into training and validation sets in a 7:3 ratio.
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Cinacalcet Improves Erythropoietin Resistance in Patients with Secondary Hyperparathyroidism Receiving Dialysis Treatment.
Curr Pharm Des
January 2025
Department of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Introduction: Chronic Kidney Disease (CKD) is recognized as a major global public health problem. Dialysis is the mainstay of treatment for patients with end-stage renal disease and can prolong survival in patients with CKD. As patient survival increases, the treatment of complications becomes more important.
View Article and Find Full Text PDFNationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study.
Ann Transl Med
December 2024
Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Background: Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD.
Methods: We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD.
PASS: A scoring system to evaluate persistent kidney injury in critically ill ICU adult patients.
F1000Res
January 2025
Department of Nephrology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, 575001, India.
Background: We evaluated if the course of recovery from sepsis-induced acute kidney injury (AKI) can be predicted using variables collected at admission.
Methods: A total of 63 patients admitted for sepsis-induced AKI in our Mangalore ICU were evaluated and baseline demographic and clinical/laboratory parameters, including serum creatinine (SCr), base excess (BE), Plethysmographic Variability Index (PVI), Caval Index, R wave variability index (RVI), mean arterial pressure (MAP) and renal resistivity index (RI) using renal doppler and need for inotropes were assessed on admission. Patients were managed as per standard protocol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!